Inventor · disambiguated record
Eric A. Murphy
Also filed as: MURPHY ERIC · MURPHY ERIC A · MURPHY ERIC ANTHONY
23 granted patents·11 pending applications·154 citations·filing 1998–2025
94Inventor score
Files withKINNATE BIOPHARMA INC15ALTEROME THERAPEUTICS INC5AFFYMETRIX INC4AMITECH THERAPEUTIC SOLUTIONS INC3KHORA SPV 1 LLC2
Top patents by PatentIndex Score
34 records- 0196US11407737B2Inhibitors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2021·Granted Aug 9, 2022·8 cites·30 claims
- 0296US11098031B1Inhibitors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2020·Granted Aug 24, 2021·12 cites·30 claims
- 0395US11377431B2Inhibitors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2021·Granted Jul 5, 2022·7 cites·30 claims
- 0495US11345681B1Inhibitors of fibroblast growth factor receptor kinasesKINNATE BIOPHARMA INC·Filed 2021·Granted May 31, 2022·4 cites·19 claims
- 0591US12312336B2Inhibitors of RAF kinasesPF MEDICAMENT·Filed 2021·Granted May 27, 2025·2 cites·20 claims
- 0691US11999730B1AKT1 modulatorsALTEROME THERAPEUTICS INC·Filed 2023·Granted Jun 4, 2024·2 cites·29 claims
- 0791US10894788B2Inhibitors of cyclin-dependent kinasesKINNATE BIOPHARMA INC·Filed 2019·Granted Jan 19, 2021·5 cites·29 claims
- 0889US11746095B2Inhibtors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2022·Granted Sep 5, 2023·1 cites·10 claims
- 0988US11684615B2Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitorsBIOSPLICE THERAPEUTICS INC·Filed 2020·Granted Jun 27, 2023·2 cites·31 claims
- 1086US11918587B2Treatment of cancer with a RAF inhibitorKINNATE BIOPHARMA INC·Filed 2023·Granted Mar 5, 2024·2 cites·20 claims
- 1186US6673579B2Methods and compositions for multiplex amplification of nucleic acidsAFFYMETRIX INC·Filed 2001·Granted Jan 6, 2004·24 cites·10 claims
- 1285US10806726B2Methods of using indazole-3-carb oxamides and their use as Wnt/B-catenin signaling pathway inhibitorsSAMUMED LLC·Filed 2017·Granted Oct 20, 2020·5 cites·4 claims
- 1384US6333179B1Methods and compositions for multiplex amplification of nucleic acidsAFFYMETRIX INC·Filed 1998·Granted Dec 25, 2001·73 cites·13 claims
- 1482US9212151B2Heterocyclic compounds useful for kinase inhibitionAMITECH THERAPEUTIC SOLUTIONS INC·Filed 2015·Granted Dec 15, 2015·4 cites·21 claims
- 1579US2025092040A1Akt1 modulatorsALTEROME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1677US12209087B2AKT1 modulatorsALTEROME THERAPEUTICS INC·Filed 2024·Granted Jan 28, 2025·0 cites·20 claims
- 1777US2025346610A1SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSALTEROME THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1873US12466842B2Substituted pyrido [4,3-d]pyrimidines as KRAS modulatorsALTEROME THERAPEUTICS INC·Filed 2025·Granted Nov 11, 2025·0 cites·30 claims
- 1970US8957216B2Heterocyclic compounds useful for kinase inhibitionARNOLD LEE DANIEL·Filed 2011·Granted Feb 17, 2015·2 cites·12 claims
- 2070US7053206B2Methods and compositions for multiplex amplification of nucleic acidsAFFYMETRIX INC·Filed 2003·Granted May 30, 2006·1 cites·18 claims
- 2169US2025333399A1Inhibitors of fibroblast growth factor receptor kinasesKHORA SPV 1 LLC·Filed 2025·Application pending·0 cites
- 2268US2005112657A1Methods and compositions for multiplex amplification of nucleic acidsAFFYMETRIX INC·Filed 2004·Application pending·0 cites
- 2366US12331039B2Inhibitors of fibroblast growth factor receptor kinasesKHORA SPV 1 LLC·Filed 2022·Granted Jun 17, 2025·0 cites·14 claims
- 2466US2022340543A1Inhibitors of raf kinasesKINNATE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2562US11390618B2Inhibitors of cyclin-dependent kinasesKINNATE BIOPHARMA INC·Filed 2020·Granted Jul 19, 2022·0 cites·20 claims
- 2655US2023374015A1Inhibitors of fibroblast growth factor receptor kinasesKINNATE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2755US2025032458A1Treatment of cancer with an fgfr kinase inhibitorKINNATE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2853US11447493B2Inhibitors of cyclin-dependent kinasesKINNATE BIOPHARMA INC·Filed 2019·Granted Sep 20, 2022·0 cites·19 claims
- 2953US2023074545A1Treatment of cancer with cdk12/13 inhibitorsKINNATE BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 3052US2022388990A1Inhibitors of cyclin-dependent kinasesKINNATE BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 3151US10214513B2Heterocyclic compounds useful for kinase inhibitionAMITECH THERAPEUTIC SOLUTIONS INC·Filed 2015·Granted Feb 26, 2019·0 cites·3 claims
- 3251US2023081390A1Inhibitors of raf kinasesKINNATE BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 3342US9260417B2Therapeutic methods and compositions involving allosteric kinase inhibitionMURPHY ERIC A·Filed 2011·Granted Feb 16, 2016·0 cites·19 claims
- 3441US2016237064A1Therapeutic methods and compositions involving allosteric kinase inhibitionAMITECH THERAPEUTIC SOLUTIONS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Eric A. Murphy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →